EPO Patents = 3

Forward Citations = 44

Loading Chart...

3 inventors (with patents filed for the assignee):

Dror Mevorach (7 out of 16 patents)

Shai Novik (4 out of 14 patents)

Inna Reiner (2 out of 2 patents)

7 patents: Sort by Forward Citations

1. 11318163 - Combination immune therapy and cytokine control therapy for cancer treatment (2022-05-03),

2. 11304976 - Combination immune therapy and cytokine control therapy for cancer treatment (2022-04-19),

3. 11000548 - Combination immune therapy and cytokine control therapy for cancer treatment (2021-05-11),

4. 10927343 - Therapeutic apoptotic cell preparations, method for producing same and uses thereof (2021-02-23),

5. 10857181 - Therapeutic pooled blood apoptotic cell preparations and uses thereof (2020-12-08),

6. 10077426 - Therapeutic apoptotic cell preparations, method for producing same and uses thereof (2018-09-18),

7. 9567568 - Method of preparing apoptotic monocytes (2017-02-14),

Company Overview

Enlivex Therapeutics Ltd is a clinical-stage biotechnology company focused on developing and commercializing novel immunotherapies for infectious diseases and cancer. Their lead product candidate, Allocetra, is a potential treatment for severe sepsis and COVID-19. Enlivex is dedicated to improving patient outcomes through the modulation of the immune system.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

7 Patents

#9 in Nes-Ziona

#911 in Israel

Nes-Ziona, Israel

Enlivex Therapeutics Ltd

Forward Citations = 44

3 inventors:

Dror Mevorach (7 out of 16 patents)

Shai Novik (4 out of 14 patents)

Inna Reiner (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Enlivex Therapeutics Ltd. Retrieved from https://idiyas.com/company/enlivex-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

3 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]